NeuroOne Announces First Quarter Fiscal 2026 Financial Results Release Date and Conference Call Details

NeuroOne Medical Technologies Corporation, trading on Nasdaq under the symbol NMTC, has scheduled the release of its financial results for the first quarter of fiscal year 2026, which ended on December 31, 2025. The announcement will occur before the market opens on Tuesday, February 17, 2026. Following the release, the company's management will host a conference call and webcast at 8:30 a.m. Eastern Time to review the quarterly financial performance, deliver a corporate update, and address questions from participants.

The importance of this financial disclosure lies in its potential to provide insights into NeuroOne's operational progress and financial health as it continues to develop and market its medical technology solutions. The company focuses on transforming surgical diagnosis and treatment for neurological disorders through its FDA-cleared product families, including the Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System for the brain, and OneRF Trigeminal Nerve Ablation System. These technologies aim to reduce hospitalizations, lower healthcare costs, and improve patient outcomes by integrating diagnostic and therapeutic functions.

Investors and stakeholders can access the conference call by dialing 888-506-0062 toll-free in the United States or 973-528-0011 internationally, using participant access code 393318. Alternatively, a live webcast will be available through the NMTC FY Q1 2026 Earnings Call Webcast link. Participants are advised to join at least five minutes early to ensure timely access. A replay of the call will be accessible until March 3, 2026, by calling 877-481-4010 in the United States or 919-882-2331 internationally with replay passcode 53566, or via the webcast replay using the same link.

The implications of this financial report extend beyond mere numbers, as it may reflect the company's advancements in its research and development initiatives, including drug delivery and spinal cord stimulation programs. By analyzing the results, the market can gauge NeuroOne's trajectory in a competitive medical technology sector, where innovation and regulatory milestones are critical. The call offers a platform for management to elaborate on strategic directions and operational efficiencies, which could influence investor confidence and the company's ability to fund future growth. For more information about NeuroOne and its technologies, visit https://nmtc1.com.